Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET

Acetylcholinesterase (AChE) activities in the brain of three patients with AD were measured once before and once during donepezil treatment (5 mg/d in two patients, 3 mg/d in one patient) using PET and N-[11C]methylpiperidin-4-yl acetate. Donepezil reduced k3 values, an index of AChE activity, in the cerebral cortex by 39 ± 5%. All patients showed some degree of symptomatic improvement, and it was concluded that this improvement was likely caused by improved cholinergic activity by inhibition of AChE in the brain.

[1]  G. Chazot,et al.  The Physiology and Pharmacology of Melatonin in Humans , 1998, Hormone Research in Paediatrics.

[2]  S. Tanada,et al.  Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: A positron emission tomography study , 2000, Annals of neurology.

[3]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[4]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[5]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[6]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[7]  Hitoshi Shinotoh,et al.  Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease , 1997, The Lancet.

[8]  S. Minoshima,et al.  In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease , 1999, Neurology.

[9]  O. Hjemdal,et al.  A new rating scale for adult resilience: what are the central protective resources behind healthy adjustment? , 2003, International journal of methods in psychiatric research.

[10]  S Tanada,et al.  Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy , 1999, Annals of neurology.